Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. (ATRA) for securities fraud, affecting shareholders who acquired shares between May 20, 2024, and January 9, 2026, with a deadline for lead plaintiff motion set for May 22, 2026 [1]. Summary by Relevant Sections Company Background - Atara Biotherapeutics, Inc. is a biotechnology company focused on developing therapies for patients with serious diseases, including its Epstein-Barr treatment, tabelecleucel (EBVALLO) [4]. Events Leading to the Lawsuit - On January 16, 2025, Atara received a Complete Response Letter (CRL) from the FDA regarding its BLA for tabelecleucel, indicating that the application would not be approved in its current form, leading to a stock price drop of $5.33, or 40.5%, closing at $7.83 per share [4]. - On January 21, 2025, Atara announced a clinical hold on its active IND applications due to GMP compliance issues, resulting in a further stock price decline of $0.52, or 7.9%, to close at $6.05 per share [5]. - On January 12, 2026, Atara disclosed another CRL regarding the resubmitted tabelecleucel BLA, stating that the trial's design and conduct were inadequate for evidence of effectiveness, causing the stock price to fall by $7.79, or 56.99%, to close at $5.88 per share [6][7]. Allegations in the Lawsuit - The lawsuit alleges that Atara's management made materially false and misleading statements and failed to disclose significant adverse facts about the company's business and prospects, including: 1. Manufacturing issues and deficiencies in the ALLELE study that made FDA approval unlikely [7]. 2. Overstated regulatory prospects for tabelecleucel [7]. 3. Heightened risk of regulatory scrutiny due to manufacturing issues, jeopardizing ongoing clinical trials [7]. 4. Significant negative impacts on Atara's business and financial condition [7]. 5. Misleading positive statements regarding the company's operations and prospects [7].

Core Viewpoint - A class action lawsuit has been filed against Coty Inc. for securities fraud, affecting shareholders who acquired stock between November 5, 2025, and February 4, 2026, with a deadline for lead plaintiff motions set for May 22, 2026 [1] Financial Performance - Coty reported second quarter fiscal 2026 results on February 5, 2026, which fell below market expectations, showing a 6% decrease in net revenue on a like-for-like basis, a 200 basis point decline in reported gross margins, and a 19% drop in adjusted operating income [3] - The company withdrew its 2026 EBITDA guidance and lowered its near-term outlook, anticipating a gross margin decline of 200 to 300 basis points and approximately breakeven EPS for Q3 [3] Management Commentary - Interim CEO Markus Strobel acknowledged the company's underperformance and emphasized the need for investment in operational effectiveness and marketing support [3] - CFO Laurent Mercier identified the Consumer Beauty segment as the main headwind affecting performance [3] Allegations in the Lawsuit - The lawsuit alleges that during the class period, Coty made materially false and misleading statements and failed to disclose adverse facts about its business, including underperformance in the Consumer Beauty segment, compressed margins due to increased marketing investments, and slowing growth in the Prestige fragrance market [4]

Core Viewpoint - A class action lawsuit has been filed against Lufax Holding Ltd. for securities fraud, affecting shareholders who acquired securities between April 7, 2023, and January 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that Lufax made materially false and misleading statements and failed to disclose adverse facts about its business and financial condition [5]. - Shareholders have until May 20, 2026, to file a lead plaintiff motion in the class action [1]. Group 2: Financial Disclosures - On January 27, 2025, Lufax announced plans to remove its auditor, PricewaterhouseCoopers (PwC), due to significant concerns regarding its financial disclosures, particularly for the 2022 and 2023 Annual Reports [3]. - On February 17, 2025, Lufax confirmed that its 2022 and 2023 financial reports were unreliable, revealing inaccuracies in the consolidated financial statements and restated net profit figures showing material declines [4]. Group 3: Impact on Shareholders - Following the announcement regarding the auditor's removal, Lufax's stock price dropped by $0.40, or 13.8%, closing at $2.49 per share on January 27, 2025, resulting in losses for investors [3].

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. (IBRX) for securities fraud, encouraging shareholders to inquire about their rights and potential recovery of losses [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, with a deadline for filing a lead plaintiff motion set for May 26, 2026 [1]. - The lawsuit alleges that the company's Executive Chairman, Patrick Soon-Shiong, made false claims about the lead biologic product, Anktiva, including that it "can cure and even prevent all cancer," which the FDA deemed misleading [3][4]. Group 2: Impact on Shareholders - Following the FDA's warning on March 24, 2026, ImmunityBio's stock price dropped by $1.98, or 21.12%, closing at $7.42 per share, resulting in significant losses for investors [3]. - The complaint asserts that the defendants failed to disclose material adverse facts about the company's business and operations, leading to misleading statements regarding its prospects [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Super Micro Computer, Inc. for alleged misrepresentations regarding the company's compliance with export control laws during the period from April 30, 2024, to March 19, 2026 [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning the company's controls to ensure compliance with applicable export control laws and regulations [4]. - Investors who purchased or acquired Super Micro securities during the specified period are eligible to join the class action [1][2]. - The deadline to file papers to serve as lead plaintiff for the class is May 25, 2026 [3]. Group 2: Legal Representation - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless there is a recovery [3]. - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Coty Inc. on behalf of investors who purchased or acquired its common stock between November 5, 2025, and February 4, 2026, alleging misrepresentations regarding the company's growth and performance in the beauty market [1][4]. Group 1: Lawsuit Details - The lawsuit claims that Coty misrepresented the state of its growth in the beauty market, particularly highlighting underperformance in the Consumer Beauty market, compressed margins due to increased marketing investments, and slowing growth in its Prestige fragrance segment [4]. - Investors who wish to serve as lead plaintiffs must file papers by May 22, 2026, and participation in any recovery does not require serving as lead plaintiff [3]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has represented both individual investors and large pension funds [5]. - All representation in this lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Lufax Holding Ltd for alleged misrepresentations regarding the company's internal controls, leading to materially misstated financial results [4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired Lufax securities between April 7, 2023, and January 26, 2025 [1]. - Investors interested in joining the lawsuit can contact the Investor Relations Manager for more information [2]. - A lead plaintiff must file papers by May 20, 2026, to represent the class in the litigation [3]. Group 2: Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its inception in 1993 and has a strong track record in class action litigation [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Power Solutions International, Inc. for alleged misrepresentations regarding the company's ability to meet sales demand in the data center market during the specified period [1][4]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased or acquired Power Solutions securities between May 8, 2025, and March 2, 2026 [1]. - Defendants are accused of making false statements about the company's capacity to capture sales demand for its power systems solutions [4]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file necessary documents by May 19, 2026 [3]. - Participation as a lead plaintiff is not required to share in any potential recovery from the lawsuit [3]. Group 3: Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its inception in 1993 [5].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Braskem S.A. due to significant financial losses and concerns regarding compliance with federal securities laws [1][4]. Financial Performance - Braskem disclosed a consolidated net loss of approximately R$10.96 billion for the year 2025 and has accumulated losses of around R$23.9 billion [3]. - The company's independent auditor noted a material uncertainty regarding Braskem's ability to continue as a going concern, indicating severe balance-sheet stress with current liabilities exceeding total assets [3]. Stock Performance - Following the financial disclosures, Braskem's stock experienced a decline, adversely affecting investors [3]. Legal Investigation - Johnson Fistel is examining whether Braskem's executive officers complied with federal securities laws in light of the financial issues disclosed [4].

Core Viewpoint - A securities fraud lawsuit has been filed against Aldeyra Therapeutics, Inc. following a significant drop in its stock price due to negative FDA feedback on its drug reproxalap for dry eye disease [1][2]. Group 1: Company Performance - Aldeyra Therapeutics' shares fell over 65% on March 17, 2026, after the company disclosed that the FDA issued a Complete Response Letter indicating that the application for reproxalap "failed to demonstrate efficacy in adequate and well controlled studies" [2]. - The FDA previously indicated that Aldeyra's New Drug Application (NDA) for reproxalap did not demonstrate efficacy in treating ocular symptoms associated with dry eyes and required at least one additional study to support its effectiveness [2]. Group 2: Investor Eligibility - Investors who purchased Aldeyra Therapeutics common stock between November 3, 2023, and March 16, 2026, and experienced a decline in their investment may be eligible to participate in the lawsuit, regardless of whether they sold their shares [3]. Group 3: Legal Process - The deadline for investors to seek appointment as lead plaintiff in the lawsuit is May 29, 2026, and a class has not yet been certified [4]. - Investors who have lost money are encouraged to contact Block & Leviton for more information on their rights and options [4]. Group 4: Whistleblower Information - Individuals with non-public information about Aldeyra Therapeutics are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 5: Legal Representation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].